Latest / Pharmacy Podcast Network / Journavx: A Quick Journey into the Novel Non-Opioid Pain Med | Pain Pod
Transcript
- 0:05Speaker 1: You are listening to the global network of podcasters dedicated
- 0:08Speaker 1: to the pharmacy profession. Welcome to the Pharmacy podcast Network.
- 0:20Speaker 2: This is the Pain Pod.
- 0:24Speaker 3: You want to see pain, look at me? Welcome to
- 0:34Speaker 3: the Pain Pod, the podcast for all things pain management,
- 0:39Speaker 3: hosted by the pain.
- 0:40Speaker 2: Guy, doctor Mark Grow.
- 0:47Speaker 3: We'll be collaborating with numerous pain management experts, talking about
- 0:51Speaker 3: substance usage disorders, the latest treatment modalities, and most important
- 0:57Speaker 3: important focusing on the pain of our patients as leading
- 1:00Speaker 3: providers of pain care. And now here's our host, a
- 1:06Speaker 3: man wanted in all fifty states, a suburban city like
- 1:11Speaker 3: Mountain man without the beard, from the hills of West
- 1:16Speaker 3: Virginia and certified in weapons.
- 1:19Speaker 2: Of mass destruction response. Yes, doctor Mark sly.
- 1:31Speaker 4: Welcome back everyone to the Pain Pod. So today, well,
- 1:36Speaker 4: we've got a brief episode. Okay, we'll usually give.
- 1:39Speaker 2: You enough to have a nice run or jog or.
- 1:42Speaker 4: Stroll or drive, but this one's kind of on the
- 1:45Speaker 4: beat on the street reporting here because we've got a
- 1:48Speaker 4: new pain medication hot off the presses, lots of chatter online,
- 1:53Speaker 4: the media is covering.
- 1:54Speaker 2: It's on every news station and lo and behold, we
- 1:58Speaker 2: need it on the Pain.
- 1:59Speaker 4: Pod, you know on the Farmsy podcast network. That's that's
- 2:02Speaker 4: one of the go to, you know, areas for new information.
- 2:07Speaker 4: So you know why in the world when we cover
- 2:09Speaker 4: sustragene also known as journe of acts, right, it's the
- 2:14Speaker 4: new pain medication, the new non opioid.
- 2:17Speaker 2: Dun dun dun dunt dune.
- 2:19Speaker 4: You know, in an era of the opioid crisis or
- 2:22Speaker 4: whatever we want to call it. Whenever there's a novel,
- 2:25Speaker 4: a newer medication with a mechanism of action that we
- 2:30Speaker 4: either haven't seen in a while or gets more specific
- 2:32Speaker 4: or is truly just out of the blue novel, well,
- 2:36Speaker 4: we got to cover it, right, So let's let's hop
- 2:38Speaker 4: to here, all right, So this journov acs stuff, sooustrigene,
- 2:42Speaker 4: it's a sodium channel inhibitor, right, we abbreviate that as
- 2:47Speaker 4: a NAV one point eight. And you're like, good, Gully,
- 2:50Speaker 4: is he talking MM factors again? More female gram equivalent factors?
- 2:54Speaker 2: No, no, no, no, no.
- 2:55Speaker 4: In fact, it's not even an opioid. Okay, let's throw
- 2:57Speaker 4: it out there. Hey, nolax On doesn't work on it
- 3:00Speaker 4: because it's not an opioid. Okay, I'm pretty sure unless
- 3:03Speaker 4: anyone's under a rock. You caught the headline saying, hey,
- 3:06Speaker 4: it's it's a non opioid option, right.
- 3:09Speaker 2: But you know we need more, all right.
- 3:11Speaker 4: I wish they would just get folks like us pharmacists on,
- 3:15Speaker 4: you know, the coverage of the media. When when that happens,
- 3:18Speaker 4: because we dive deeper, right, we go into things like, okay, well, how.
- 3:22Speaker 2: Do you explain this mechanism action? Well, here's how I
- 3:25Speaker 2: do it.
- 3:26Speaker 4: Okay, it's a sodium channel inhibitor, so it's working on
- 3:30Speaker 4: sodium channels. Good golly, Every college student in the last
- 3:34Speaker 4: I don't know many decades, you know, used to work
- 3:36Speaker 4: on the old sodium potassium pump. And then you know
- 3:39Speaker 4: the conducting electricity through our bodies with sodium channels. Right.
- 3:44Speaker 4: The overall idea here is that it's keeping the it's
- 3:46Speaker 4: keeping the sodium out. It keeps it out in the
- 3:48Speaker 4: extra cellular fluid. It doesn't it doesn't give it a ticket,
- 3:51Speaker 4: it doesn't let it come into the cell. That movement
- 3:55Speaker 4: usually gives it your action potential creates the electricity. Yes, folks,
- 3:59Speaker 4: we're all just like a potato battery, but we're human.
- 4:02Speaker 4: We can probably power away more than a little light bulb. Right,
- 4:05Speaker 4: maybe those LEDs these days, but that's where it's working, right,
- 4:10Speaker 4: But we've had medications in the past that work in
- 4:14Speaker 4: that same ballpark, right, light Acane or the canes come
- 4:19Speaker 4: to mind, right in an aesthetic sense, also in a
- 4:23Speaker 4: arrhythmia sense, you know, all talking about the electricity here
- 4:27Speaker 4: in our human bodies. Right now, with this new medication
- 4:30Speaker 4: suice for gain, it's the way I like, and it's
- 4:33Speaker 4: kind of like, well, we have club seats instead of
- 4:35Speaker 4: standing room only something like well I mentioned lydacane, that's
- 4:39Speaker 4: your standing room only ticket to get into the ballpark.
- 4:43Speaker 4: Or no, not super Bowl. That would cost you an
- 4:45Speaker 4: an arm, a leg and two kidneys. But anyways, this
- 4:49Speaker 4: is this new medicine is more like the club seats.
- 4:52Speaker 4: Why well, right off the bat, you're like, well, hey,
- 4:54Speaker 4: paying guy, it's probably because it's new and it costs more. Right,
- 4:57Speaker 4: we'll get there. Where I'm going with it is that
- 5:00Speaker 4: it's specific. Okay, there's multiple sodium voltage gated channels in
- 5:05Speaker 4: our body, just like we do with beta, beta one,
- 5:09Speaker 4: beta two, so on, and so forth, Alpha one and
- 5:11Speaker 4: two cannabinoids. Dare we say CB one and two well,
- 5:16Speaker 4: here we are again, but now it's with sodium voltage
- 5:18Speaker 4: gated channels navs. Right, this works on NAB one point eight.
- 5:24Speaker 4: There's others, and.
- 5:25Speaker 2: I guarantee that many of you have heard of them before,
- 5:29Speaker 2: but they were disguised.
- 5:31Speaker 4: You know, when this first realm, first time it was
- 5:34Speaker 4: talked about, it was on The Simpsons. Okay, longest running
- 5:38Speaker 4: show in the history of mankind, right, still going strong.
- 5:41Speaker 4: It's even on Disney Plus these days, the reruns anyway,
- 5:43Speaker 4: But there was an episode okay, season two, all the
- 5:48Speaker 4: way back in I believe nineteen ninety one, but season two,
- 5:51Speaker 4: episode eleven, Okay, the homer was, oh no, Well, the
- 5:56Speaker 4: fam was over I believe in Asia and they were
- 5:59Speaker 4: having sushi and the chef thought that he would cut
- 6:03Speaker 4: the blowfish incorrectly, right, and then he was told that
- 6:06Speaker 4: he had twenty four hours to live. That was basically
- 6:08Speaker 4: the episode. Right, What in the heck does that have
- 6:11Speaker 4: to do with NAV one point eight? Right, Well, that
- 6:15Speaker 4: blowfish or puffer fish is said to have a toxin
- 6:20Speaker 4: in it.
- 6:20Speaker 2: Okay, it's tetrot toxin.
- 6:24Speaker 4: It rolls off the tongue after you say it thirty
- 6:26Speaker 4: five times, but it's abbreviated is TTX. Okay, that TTX
- 6:29Speaker 4: is in the pufferfish or blowfish organs primary the liver
- 6:33Speaker 4: and you know it's it's actually banned to ever serve
- 6:38Speaker 4: liver from that blowfish, you know where Homer was in
- 6:42Speaker 4: that fake episode, obviously, right, But the intestinal bacteria produce
- 6:47Speaker 4: that TTX, the tetrot to toxin, and a little knife
- 6:52Speaker 4: slip could be the end of it for someone because
- 6:54Speaker 4: that's a toxin. It leads to death, Okay, paralysis because
- 6:59Speaker 4: it stops the action potentials, it cuts the electricity. Lights
- 7:03Speaker 4: are not home on and no one is home scenario, right.
- 7:07Speaker 4: But that's so that TTX that's in puffer fish blowfish,
- 7:12Speaker 4: you know, and what Homer proverbalia experienced. They lead to
- 7:17Speaker 4: prel since and death in mammals on the NAV one
- 7:21Speaker 4: point one, two, three, four, six and supposedly seven channels, okay,
- 7:27Speaker 4: one point each of those, but not one point eight.
- 7:30Speaker 2: Ah, that's where it comes in. So this NAV one
- 7:34Speaker 2: point eight, it's a little bit different.
- 7:35Speaker 4: Okay, it's it's uh, you don't have to worry about
- 7:38Speaker 4: the puffer fish having any action on the area was
- 7:40Speaker 4: not in that Simpsons episode, Okay, But that's where it's
- 7:44Speaker 4: at there. Okay, so we got club seats, we got
- 7:47Speaker 4: the Simpsons. What else we got here? So you know
- 7:50Speaker 4: a little other background. I doubt you've heard of this one,
- 7:53Speaker 4: but there's Brugatta syndrome. Sounds like something from a mafia movie, right,
- 7:57Speaker 4: all respect to anyone who has had this, by the way,
- 7:59Speaker 4: but it's an arrhythma disorder. It's basically linked to mutations
- 8:03Speaker 4: in the sodium channel gene, specifically the SCN five A.
- 8:09Speaker 4: Pretty sure, I remember those numbers and letters, right, but
- 8:11Speaker 4: SCN five A tried to memorize it for you folks.
- 8:14Speaker 4: But the mutations lead to, you know, a reduction in
- 8:17Speaker 4: that sodium flow, leaves it extra stular, doesn't let it
- 8:20Speaker 4: into heart muscles. Okay, major major concern there for you know,
- 8:24Speaker 4: the It's relatively rare, but those that have that. But again,
- 8:27Speaker 4: it's affecting those sodium voltage gated channels. So that's a
- 8:32Speaker 4: heck of a lot of background. You didn't hear that
- 8:34Speaker 4: on the news when it comes to Bergata, Simpsons and
- 8:36Speaker 4: club seats. When we're thinking of how the heck this
- 8:38Speaker 4: new sustragain works, right, what about the studies?
- 8:42Speaker 2: All right? It's all about the studies.
- 8:43Speaker 4: Baby, right, and the dosage imember paraphrasing Paracelsus, but lots
- 8:49Speaker 4: of different studies. But there was two phase three trials.
- 8:52Speaker 4: One was on abdominoplasty. You know what you know that
- 8:55Speaker 4: is Tommy Tuck.
- 8:57Speaker 2: Okay.
- 8:57Speaker 4: The other one was on bunyan nectomy. It's like, we're
- 9:00Speaker 4: all the cool kids hang out for all pain trials
- 9:02Speaker 4: these days. That that seems to be where it's at
- 9:05Speaker 4: right in these trials, though, it's really important to point
- 9:08Speaker 4: out that it was predominantly almost exclusively female patients, Okay,
- 9:13Speaker 4: very high percentage over ninety percent. That's different Back in
- 9:17Speaker 4: the day, it was literally the exact opposite, right, So
- 9:20Speaker 4: we got to keep that in mind. And what was
- 9:24Speaker 4: shown that the summary basically is that the efficacy was
- 9:28Speaker 4: almost mirroring that of a hydrocodon act to minifin five
- 9:32Speaker 4: three twenty five tablet.
- 9:33Speaker 2: Okay.
- 9:34Speaker 4: Now that's big when you think about it. You've got
- 9:36Speaker 4: a non opioid almost mirroring the efficacy of an opioid.
- 9:40Speaker 4: All be a lower dose, but it's an opioid naive
- 9:42Speaker 4: common dose. It's what we see in practice, right, So
- 9:46Speaker 4: you know, we're onto something there, right, Perhaps that's why
- 9:49Speaker 4: we see sad at least all over the news. But again,
- 9:53Speaker 4: almost all female patients, you know, Tommy talks and bunyan ectomies.
- 9:58Speaker 2: That's you know, that's not everything. I mean there's a
- 10:00Speaker 2: lot of pain out there, right.
- 10:02Speaker 4: Those trials led to FD approval four, specifically moderate to
- 10:07Speaker 4: severe acute pain in adults. Okay, what's that, great philosopher W. Farrell, Well,
- 10:13Speaker 4: that escalated quickly, so it's approved for all acute pain
- 10:17Speaker 4: in adults that is, you know, pain that is moderate
- 10:20Speaker 4: to severe, right, based on those two studies there, and
- 10:23Speaker 4: of course the.
- 10:23Speaker 2: Information from phase one and phase two as well, So
- 10:26Speaker 2: that's where we're at.
- 10:27Speaker 4: That's that's huge news, right, all right, we're in healthcare heck,
- 10:32Speaker 4: we're in the pharmacy realm here, right, So what else
- 10:35Speaker 4: we do we need to know here? Right? Well, food
- 10:38Speaker 4: can alter the absorption, so you got to you know,
- 10:40Speaker 4: basically we're talking eventually, we'll be talking with patients about
- 10:44Speaker 4: you know, not eating. You know the idea of taking
- 10:46Speaker 4: out an empty stomach. It's usually said to be about
- 10:48Speaker 4: an hour before or two hours after food ingestion, so
- 10:51Speaker 4: that comes into play, right, But again we're dealing with
- 10:55Speaker 4: acute pain. In this scenario, most folks want to have
- 10:58Speaker 4: that pain taken care of and the dosey dough and
- 11:02Speaker 4: do what we gotta do as far as timing for
- 11:03Speaker 4: the medicines, right, at least I would as a patient.
- 11:06Speaker 2: Wouldn't you?
- 11:07Speaker 4: Of Note, this soustreagen is also a three A substrate.
- 11:12Speaker 4: It's writing the package insert actually, and it's specific that
- 11:15Speaker 4: they don't say three A four. I know all of
- 11:17Speaker 4: our minds go there. It's like one of those psychological pictures.
- 11:20Speaker 4: If I say three A four, you hear three A four.
- 11:22Speaker 4: But if I say three a you probably still hear
- 11:25Speaker 4: three A four. Right, But it is a three A substrate.
- 11:28Speaker 4: So we got to watch out for those drug drug interactions. Hey, oh,
- 11:31Speaker 4: grape forruit juice? Right, all right, So how's a dose? Complicated? Simplistic? Complicated, simplicity,
- 11:40Speaker 4: I'll say that. So the initial dose would be one
- 11:42Speaker 4: hundred milligrams. That would be two of the pills, and
- 11:45Speaker 4: then subsequently it's fifty milligrams, which is how they are
- 11:48Speaker 4: provided every twelve hours times three doses. So in the
- 11:52Speaker 4: first two days you take two for the first dose,
- 11:55Speaker 4: and then one every twelve hours. After the second day,
- 12:00Speaker 4: then it's one of the fifty milligrams once a day.
- 12:02Speaker 4: And of course we're in the cute pain realm here,
- 12:04Speaker 4: so we're usually looking at less than two weeks, less
- 12:06Speaker 4: than fourteen days.
- 12:07Speaker 2: Okay, now hopefully you table this.
- 12:10Speaker 4: But remember we were talking about club seats instead of
- 12:12Speaker 4: standing room only compared to the canes.
- 12:14Speaker 2: You know, light it came and all that. Well, those
- 12:16Speaker 2: club seats ain't free, right, So what's the cost? All right?
- 12:20Speaker 4: We went over a lot of the ups and downs
- 12:22Speaker 4: when it comes to this new medication, but the cost
- 12:26Speaker 4: is said to be, and this is from media sources here,
- 12:29Speaker 4: fifteen bucks a pill. So obviously one of the biggest things.
- 12:35Speaker 4: You know, that's initial dose is thirty and then over
- 12:38Speaker 4: the first two days you're looking at another three doses
- 12:41Speaker 4: and then one a day. Right, it adds up pretty quick.
- 12:44Speaker 4: But again we are in the cute realm here, so
- 12:46Speaker 4: we're not talking thousands. This is in the acute pain
- 12:49Speaker 4: realm for adults, for monitor to severe acute pain in adults.
- 12:53Speaker 4: What we really, you know, would need to see here
- 12:56Speaker 4: for the actual access is you know, the manufact actually
- 13:00Speaker 4: representatives being out there working with health systems, working with
- 13:04Speaker 4: coverages to ensure that there would be actual coverage and
- 13:08Speaker 4: realistic copays to actually have this out there helping patients,
- 13:12Speaker 4: because from what we just talked about, through everything, it's
- 13:14Speaker 4: a non opioid option, got some novelty to it. We've got,
- 13:18Speaker 4: you know, the safety and efficacy ideas that we went over,
- 13:21Speaker 4: and the access includes cost and coverage as well too,
- 13:25Speaker 4: So TBD to be determined in that. Hopefully we have
- 13:29Speaker 4: another option here for our patients. Finally, right, It's it's
- 13:33Speaker 4: been a while, it's been like twenty years since we
- 13:35Speaker 4: had a novel idea there, but again we've had the
- 13:39Speaker 4: sodium channel realm that ballpark before.
- 13:42Speaker 2: It's just we had standing room only seats. Now we
- 13:44Speaker 2: got some club seats.
- 13:45Speaker 4: Right, all right, folks, hope this helps you out as
- 13:49Speaker 4: far as a quick rundown with a little bit of
- 13:51Speaker 4: entertainment in the background. You know, probably didn't expect the
- 13:54Speaker 4: Simpsons or Burgatta coming in here, right, but let's rock
- 13:57Speaker 4: out those club seats for helping our patients and pay
- 14:00Speaker 4: until the next episode. Folks, I thank you Pain pod Nation,
- 14:05Speaker 4: and I wish you a great day every day.
- 14:08Speaker 3: If you'd like to join Mark on the Pain pod
- 14:11Speaker 3: Send us an email to publish your at pharmacypodcast dot com,
- 14:17Speaker 3: and make sure to share the show and subscribe on
- 14:19Speaker 3: your favorite podcast directory.
- 14:22Speaker 2: Thanks for listening.